Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of LIMN will decline by -23.77% over the next 2 Weeks and hit $0.82 by Tuesday, February 17, 2026. In that time frame, LIMN's share price is expected to range between $0.70 and $0.93.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Feb 17, 2026 | 0.70 | 0.82 | 0.93 |
| Feb 16, 2026 | 0.63 | 0.76 | 0.87 |
| Feb 13, 2026 | 0.69 | 0.80 | 0.92 |
| Feb 12, 2026 | 0.74 | 0.86 | 0.98 |
| Feb 11, 2026 | 0.70 | 0.82 | 0.94 |
| Feb 10, 2026 | 0.71 | 0.83 | 0.93 |
| Feb 9, 2026 | 0.67 | 0.77 | 0.89 |
| Feb 6, 2026 | 0.70 | 0.82 | 0.93 |
| Feb 5, 2026 | 0.76 | 0.88 | 1.00 |
| Feb 4, 2026 | 0.72 | 0.84 | 0.95 |
LIMN shares rose +87.36% in Tuesday, February 3, 2026's trading session, rising from a previous close of $0.57 to move at $1.07. The stock demonstrated notable intraday movement (see LIMN's key stats for a full breakdown), fluctuating between $0.63 and $1.22, a +92.82% trading range. While recent weeks have seen some volatility, LIMN has managed to secure a +49.55% gain over the past 2 weeks. The upward price movement was accompanied by increased trading volume, with approximately 75.59M shares changing hands, 75.5M more than the previous session. This amounted to $80.88M in total market activity.
Will LIMN Continue Its Downward Trend?
According to analyst ratings and projections for LIMN, Liminatus Pharma, Inc. Class A Common Stock shares are anticipated to decrease by -14.54%, potentially reaching $0.93 per share by February 17, 2026. Short-term technical indicators for LIMN currently suggest a bearish sentiment. This aligns with the stock's recent performance, as it has recorded 19 negative trading days within the past 30 sessions. Based on the LIMN stock forecast, now is not the best time to buy LIMN stock because its current trading price is +31.18% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on LIMN covering social and institutional perspectives.
LIMN Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into LIMN's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 60.04% to 74.15%) suggest the stock is showing bullish momentum with some volatility. The 50-day RSI, at 48.29%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 48.61%, maintains a neutral outlook for the long term. Insights into LIMN's shareholder base show how institutional investors are positioning themselves during these momentum shifts
Liminatus Pharma Class A Common Stock Short-Term Forecasts
LIMN Forecast For Next 5 Days
Our algorithm anticipates Liminatus Pharma Class A Common Stock (LIMN) stock could hit $0.49 by Feb 10, 2026. This represents a -54.17% fall from today's price, following a -5.21% change over the past five days.
LIMN Forecast For Next 30 Days
Based on analysis of market trends, the outlook for Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $0.44, which would mean a -58.88% decrease from the current price of $1.07. Projections for this period range from a high of $0.65 to a low of $0.23.
LIMN Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for Liminatus Pharma Class A Common Stock's price over the next three months point to a drop. LIMN stock is expected to peak at $0.99 on Feb 05, 2026 before potentially dipping to $0.00 on May 01, 2026. On average, LIMN is likely to trade around $0.16 in the coming 90 days.
Liminatus Pharma Class A Common Stock Stock Forecast 2025
Based on our predictive models, Liminatus Pharma Class A Common Stock (LIMN) is expected to trade between $0.00 and $0.99 throughout 2026. This would result in an average price of $0.05, potentially offering investors a -95.33% return from current levels.
Liminatus Pharma, Inc. Class A Common Stock Monthly Forecast 2026–2027
February 2026
According to our latest forecast models, Liminatus Pharma, Inc. Class A Common Stock (LIMN) is positioned to show a strong performance in February 2026. The price is predicted to move between $0.00 and $0.99, settling at an average of $0.26. This could translate to a -75.70% loss.
March 2026
Based on current market signals, Liminatus Pharma, Inc. Class A Common Stock is projected to trend march 2026. We forecast a trading range from $0.00 to $0.75, with a likely average price of $0.14. Investors could expect a potential return of -86.92%.
April 2026
Our predictive algorithms indicate Liminatus Pharma, Inc. Class A Common Stock stock may see a shift in April 2026. The expected range spans $0.00–$0.78, with an average target of $0.09. This represents a cautious outlook and a possible loss of -91.59%.
May 2026
Analyzing established trends, Liminatus Pharma, Inc. Class A Common Stock looks set to move in May 2026. Projections place the stock between $0.00 and $0.71, averaging around $0.03. This suggests a -97.20% loss from current levels.
June 2026
Market indicators suggest Liminatus Pharma, Inc. Class A Common Stock could experience notable changes during June 2026. Prices could fluctuate within $0.00 to $0.62, with a midpoint forecast of $0.02. The stock might deliver a -98.13% loss.
July 2026
Forecasting for July 2026, models estimate that Liminatus Pharma, Inc. Class A Common Stock may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $0.64, averaging $0.01. This signals a cautious trajectory with potential returns around -99.07%.
August 2026
According to our latest forecast models, Liminatus Pharma, Inc. Class A Common Stock (LIMN) is positioned to show a strong performance in August 2026. The price is predicted to move between $0.00 and $0.65, settling at an average of $0.00. This could translate to a -100.00% loss.
September 2026
Based on current market signals, Liminatus Pharma, Inc. Class A Common Stock is projected to trend september 2026. We forecast a trading range from $0.00 to $0.66, with a likely average price of $0.00. Investors could expect a potential return of -100.00%.
October 2026
Our predictive algorithms indicate Liminatus Pharma, Inc. Class A Common Stock stock may see a shift in October 2026. The expected range spans $0.00–$0.64, with an average target of $0.00. This represents a cautious outlook and a possible loss of -100.00%.
November 2026
Analyzing established trends, Liminatus Pharma, Inc. Class A Common Stock looks set to move in November 2026. Projections place the stock between $0.00 and $0.66, averaging around $0.00. This suggests a -100.00% loss from current levels.
December 2026
Market indicators suggest Liminatus Pharma, Inc. Class A Common Stock could experience notable changes during December 2026. Prices could fluctuate within $0.00 to $0.62, with a midpoint forecast of $0.00. The stock might deliver a -100.00% loss.
January 2027
Forecasting for January 2027, models estimate that Liminatus Pharma, Inc. Class A Common Stock may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $0.65, averaging $0.00. This signals a cautious trajectory with potential returns around -100.00%.
February 2027
According to our latest forecast models, Liminatus Pharma, Inc. Class A Common Stock (LIMN) is positioned to show a strong performance in February 2027. The price is predicted to move between $0.00 and $0.51, settling at an average of $0.00. This could translate to a -100.00% loss.
LIMN's history of dividends and stock splits also plays a role in long-term investor confidence.